Who
Freda C. Lewis-Hall
Director
Company insider
Files Form 4 as: Director, Pyxis Oncology; Director, CDT Equity; Director and 10% owner, SpringWorks Therapeutics; Director, Exact Sciences; Director, 1Life Healthcare; Executive Vice President, Pfizer; Director, Tenet Healthcare; EVP, Medicines Development, Vertex Pharmaceuticals.
In numbers
- Trades disclosed
- 234
- Buys
- 1
- Sells
- 5
- Bought
- $900K
- Sold
- $1.2M
- Companies
- 8
- Companies where not an officer
- 6
- First trade
- 18 Jun 2008
- Last trade
- 24 Mar 2026
- Last filed
- 25 Mar 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 24 Mar 2026filed 25 Mar 2026 | PYXS Pyxis Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —45,867 at $0.00 | filing |
| 24 Mar 2026filed 25 Mar 2026 | PYXS Pyxis Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —45,867 at $0.00 | filing |
| 12 Aug 2025filed 26 Aug 2025 | CDT CDT EquityBiotechnology | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 5 Aug 2025filed 26 Aug 2025 | CDT CDT Equityoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 1 Jul 2025filed 2 Jul 2025 | SpringWorks Therapeuticsoption or derivative | SEC FORM 4 Code D | —29,983 | filing |
| 1 Jul 2025filed 2 Jul 2025 | SpringWorks Therapeuticsoption or derivative | SEC FORM 4 Code D | —7,464 | filing |
| 1 Jul 2025filed 2 Jul 2025 | SpringWorks Therapeuticsoption or derivative | SEC FORM 4 Code D | —15,318 | filing |
| 1 Jul 2025filed 2 Jul 2025 | SpringWorks Therapeuticsoption or derivative | SEC FORM 4 Code D | —13,774 | filing |
| 1 Jul 2025filed 2 Jul 2025 | SpringWorks Therapeuticsoption or derivative | SEC FORM 4 Code D | —12,216 | filing |
| 1 Jul 2025filed 2 Jul 2025 | SpringWorks Therapeutics | SEC FORM 4 Code D | —24,727 | filing |
| 14 May 2025filed 15 May 2025 | SpringWorks Therapeutics | SEC FORM 4 Code A | —10,060 at $0.00 | filing |
| 31 Mar 2025filed 2 Apr 2025 | PYXS Pyxis Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | $36K36,979 at $0.98 | filing |
| 30 Mar 2025filed 1 Apr 2025 | CDT CDT EquityBiotechnology | SEC FORM 4 Code A | $42K47,612 at $0.89 | filing |
| 18 Dec 2024filed 20 Dec 2024 | CDT CDT Equityoption or derivative · Biotechnology | SEC FORM 4 Code A | $29K420,000 at $0.07 | filing |
| 18 Nov 2024filed 20 Nov 2024 | CDT CDT EquityBiotechnology | SEC FORM 4 Code A | $39K437,976 at $0.09 | filing |
| 16 May 2024filed 17 May 2024 | SpringWorks Therapeuticsoption or derivative | SEC FORM 4 Code A | —12,216 at $0.00 | filing |
| 16 May 2024filed 17 May 2024 | SpringWorks Therapeutics | SEC FORM 4 Code A | —4,095 at $0.00 | filing |
| 22 Apr 2024filed 24 Apr 2024 | CDT CDT Equityoption or derivative · Biotechnology | SEC FORM 4 Code A | —400,664 | filing |
| 22 Apr 2024filed 24 Apr 2024 | CDT CDT Equityoption or derivative · Biotechnology | SEC FORM 4 Code A | —103,397 | filing |
| 26 Mar 2024filed 28 Mar 2024 | PYXS Pyxis OncologyBiotechnology | SEC FORM 4 Code A | —35,219 at $0.00 | filing |
News
Bristol Myers is Cheaper Than Pfizer, but Its 40% Earnings Jump Has a CatchPFE · insidermonkey.com · 19 Oct 2026Hong Kong and Macau suspend Covid Pfizer/BioNTech vaccine over packaging flawPFE · theguardian.com · 19 Oct 2026Pfizer vs. AbbVie: Is the Cheaper Pharma Stock Really the Better Investment?PFE · insidermonkey.com · 16 Oct 2026Head to Head Analysis: Caribou Biosciences (NASDAQ:CRBU) & Vertex Pharmaceuticals (NASDAQ:VRTX)VRTX · tickerreport.com · 14 Oct 2026Vertex Pharmaceuticals Incorporated: Vertex to Present New Data on ALYFTREK at the North American Cystic Fibrosis ConferenceVRTX · finanznachrichten.de · 9 Oct 2026
0 headlines in the last 90 days name Freda C. Lewis-Hall; 5 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.